Pacira Pharmaceuticals, Inc. stock performance trend indicates that the stock price has rallied 42.34% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 38.52% . Looking at the past 52 week period, the stock price is down -0.88% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Pacira Pharmaceuticals, Inc. has a negative value of -28.94 compared to overall market performance.Pacira Pharmaceuticals, Inc. is having a Relative Strength Index of 56.16 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has climbed 1.61% in the past week and advanced 8.47% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 1.37% and the outperformance has advanced to 7.23% for the last 4 weeks period.
For the current week, the company shares have a recommendation consensus of Buy. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) stock ended Friday session in the red zone in a volatile trading. The stock closed down 1.55 points or 3.17% at $47.4 with 1,528,589 shares getting traded. Post opening the session at $48.75, the shares hit an intraday low of $46.65 and an intraday high of $48.75 and the price was in this range throughout the day. The company has a market cap of $1,892 million and the number of outstanding shares has been calculated to be 39,925,108 shares. The 52-week high of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is $65.64 and the 52-week low is $29.95.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by H.C. Wainwright on Mar 2, 2017 to Buy, Raises Price Target to $ 59 from a previous price target of $48 .Pacira Pharmaceuticals Inc was Initiated by Canaccord Genuity on Feb 22, 2017 to Buy, Price Target of the shares are set at $55.Pacira Pharmaceuticals Inc was Initiated by H.C. Wainwright on Jan 3, 2017 to Buy, Price Target of the shares are set at $43.Company shares were Reiterated by Janney on Dec 30, 2016 to Neutral, Raises Price Target to $ 34 from a previous price target of $31 .Pacira Pharmaceuticals Inc was Reiterated by Mizuho on Dec 21, 2016 to Buy, Lowers Price Target to $ 41 from a previous price target of $46 .
Company has reported several Insider transactions to the SEC, on Jan 19, 2017, James S Scibetta (President) sold 20,000 shares at 38.68 per share price.On Jan 19, 2017, David M Stack (CEO and Chairman) sold 15,000 shares at 38.59 per share price.On Jun 8, 2016, Lauren Bullaro Riker (Vice President, Finance) sold 938 shares at 47.67 per share price.
Pacira Pharmaceuticals Inc Last issued its quarterly earnings results on Mar 1, 2017. The company reported $0.09 EPS for the quarter, beating the analyst consensus estimate by $ 0.08. Analyst had a consensus of $0.01. The company had revenue of $72.90 million for the quarter, compared to analysts expectations of $73.07 million. The companys revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc. is based in New Jersey.